臨床試驗

SIMPLAAFY Clinical Trial

NCT：NCT06521463 · ACTIVE_NOT_RECRUITING

NCT IDNCT06521463

狀態ACTIVE_NOT_RECRUITING

開始日期2024-10-01

SponsorBoston Scientific Corporation (INDUSTRY)

First posted2024-07-26

Last updated2026-09-11

簡要摘要

The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。